NasdaqGS:ACADBiotechs
Stronger 2026 Outlook After Mixed Q2 Results Might Change The Case For Investing In ACAD (ACAD)
In August 2026, ACADIA Pharmaceuticals Inc. reported past second-quarter 2026 results showing revenue of US$307.96 million and net income of US$31.5 million, with earnings per share from continuing operations of US$0.18, alongside higher year-to-date revenue but lower net income compared with the same period in 2025.
On the same day, the company raised its full-year 2026 guidance, lifting projected total revenues to US$1.24–US$1.30 billion and increasing expected DAYBUE global net product...